[{"orgOrder":0,"company":"GSK","sponsor":"Woodward Pharma Services","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Omega-3-Acid Ethyl Esters 90","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"GSK \/ Woodward Pharma","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Woodward Pharma"}]

Find Clinical Drug Pipeline Developments & Deals for OMEGA-3 ACID ETHYL ESTERS

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : Woodward Pharma Services LLC, has acquired Lovaza (LO-VEY-ZA) soft gelatin capsules indicated as an adjunct to diet to reduce triglyceride levels in adult patients with severe (greater than or equal to 500 mg/dL) hypertriglyceridemia from GlaxoSmithKline...

                          Brand Name : Lovaza

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          August 18, 2021

                          Lead Product(s) : Omega-3-Acid Ethyl Esters 90

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Approved

                          Sponsor : Woodward Pharma Services

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank